HDAC9 and AL amyloidosis: Panobinostat is a pan-HDAC inhibitor recently approved by the FDA in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent [Farydak® US Prescribing Information, 2015].